DOCSLIB.ORG

Systemic Embolism in Mitral Valve Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Systemic Embolism in Mitral Valve Disease Br Heart J: first published as 10.1136/hrt.32.1.26 on 1 January 1970. Downloaded from British HeartJournal, 1970, 32, 26. Systemic embolism in mitral valve disease N. Coulshed, E. J. Epstein, C. S. McKendrick, R. W. Galloway, and E. Walker From Liverpool Regional Cardiac Centre, Sefton General Hospital, Liverpool I5 The analysis of a series of 839 cases of mitral valve disease has shown the following. (a) Systemic embolism is as common with mitral regurgitation as with mitral stenosis. (b) Atrialfibrillation, with clot formation in the atrium, is the main cause predisposing to systemic embolism. (c) Mitral valve calcification is important only in that it predisposes to operative emboli. (d) Atrial appendage size has no influence on the occurrence ofsystemic embolism, and atrial appendagectomy has no influence on the occurrence of post-operative embolism. (e) Only in patients with atrial fibrillation and an operable valve, is there any reduction in the number of emboli after surgery. Certain guide-lines with regard to treatment are suggested. Peripheral arterial embolization is a serious, has been undertaken, we have tried to evaluate sometimes fatal, complication of mitral valve its usefulness in the prevention of systemic and Bern- emboli. disease. Askey (I957) and Askey Of the 839 patients, 28 had systemic emboli stein (I960) state that a first recognized before coming under review, but each of these embolus is fatal in about one in six so affec- patients was known to have had mitral valve ted, and that one-half of the survivors die disease before the embolism, and in no case was within three years, half of these because of mitral valve disease recognized because of the recurrent embolism. Surgical measures de- occurrence of an embolus. For the purpose of signed to improve valve function, and to this review, those patients having had systemic http://heart.bmj.com/ remove potential sources of clot formation, embolism as a result of bacterial endocarditis have been advocated for the prevention of were excluded. are As judged by the usual criteria, i.e. clinical, this hazard. Among the many reports electrocardiographic, and radiological, 737 patients those of Madden (I949), Belcher and Somer- had predominant mitral stenosis, and I02 had ville (I955), Glover (I956), Turner and mitral regurgitation. This was an arbitrary divi- Fraser (1956), Ellis, Harken, and Black sion, and occasionally it was difficult to decide (I959), Baker and Hancock (i960), and which was the dominant lesion, but stenosis Learoyd et al. (I960). Kellogg et al. (I96I) was always considered the most important lesion on October 1, 2021 by guest. Protected copyright. and Taber and Lam (I960) emphasized the in those cases put forward for closed mitral possible hazards of emboli occurring at valvotomy. operation, but Ellis and Harken (I96I) in a In all, 74 patients (8 8°'%) had more than trivial their reasserted aortic valve disease, and 17 of these had closed further review of patients mitral and aortic valvotomy; 8 patients were found their belief in the protective value of mitral to have organic tricuspid valve disease, the diag- valvotomy against further emboli. They also nosis being based mainly on catheter findings, thought that where mitral stenosis was and in 3 of the 8, closed mitral and tricuspid present, the occurrence of a systemic embo- valvotomy was performed. lus was in itself an indication for operation. Results Subjects The total incidence of embolism is shown in This paper is based on 839 cases of rheumatic Table i for mitral stenosis and in Table 2 for mitral valve disease seen at the Liverpool Regional mitral regurgitation, with reference to the Cardiac Centre between I952 and i965. Where cardiac rhythm, the age of the patient, and follow-up was possible, assessments were made at disability graded according to the classifica- 6-monthly intervals by at least one of the authors. tion of the New York Heart Association We have attempted to study the incidence of arterial embolism, together with possible factors (I964). in its causation; and where cardiac operation In both groups, there is an increasing incidence of embolic episodes with increas- Received I6 January i969. ing age and with atrial fibrillation, but not Br Heart J: first published as 10.1136/hrt.32.1.26 on 1 January 1970. Downloaded from Systemic embolism in mitral valve disease 27 TABLE I Incidence of systemic emboli in 737 cases of mitral stenosis Diseility Sinus rhythm Atrialfibrillation and atrtalfibril- lation combined Age 35 and below Age 36 and above Age 35 and below Age 36 and above All ages Total Emboli Total Emboli Total Emboli Total Emboli Total Emboli cases cases cases cases cases 0, 1, 2 146 6 I28 17 32 10 158 64 464 97 3 4I 2 52 5 12 2 83 19 I88 28 4 I0 I 15 0 7 2 53 I2 85 I5 Totals 197 9 195 22 5I I4 294 95 737 140 TABLE 2 Incidence of systemic emboli in 102 cases of mitral regurgitation Disability Sinus rhythm grade Sinus rhythm Atrial fibrillation and atrialfibril- lation combined Age 35 and below Age 36 and above Age 35 and below Age 36 and above All ages Total Emboli Total Emboli Total Emboli Total Emboli Total Emboli cases cases cases cases cases 0, 1, 2 25 0 10 2 7 0 i6 3 58 5 3 I 0 I 0 5 I I6 6 23 7 4 I I I 0 7 2 I2 2 2I 5 Totals 27 I 12 2 19 3 44 II I02 I7 http://heart.bmj.com/ with a worsening disability. With dominant mitral valve disease were referred only after mitral stenosis, emboli occurred in 31 Out of a major embolus had occurred. Of the 28, 9 392 patients with sinus rhythm (8%), and were in sinus rhythm, and I9 in atrial fibril- in I09 Out of 345 with atrial fibrillation lation; 24 had a disability of grade 2 or less, (3I 5%). With dominant mitral regurgitation, and 4 were aged 35 or less. emboli occurred in 3 out of 39 patients with sinus rhythm (7 7%), and in 14 out of 63 Pre-operative emboli, atrial thrombus, with atrial fibrillation (22%). and atrial appendage size In most cases, on October 1, 2021 by guest. Protected copyright. The incidence of embolism is similar embolism must be related to the formation in both groups, and when considered to- of thrombus in the left atrium or ventricle, gether, the figures range from IO emboli in and certainly if clot is present it must increase 224 patients aged,35 or less in sinus rhythm the risk of producing emboli at operation. (4 4%)°, to Io6 emboli in 338 patients aged Unfortunately, a history of embolism does 36 or more with atrial fibrillation (3I 6%). not help in predicting the presence of clot QX the I57 patients with emboli, 32 (20%) discoverable at operation, since, in this were in sinus rhythm when examined. None present series, such clot was found in only of these patients gave a history of paroxysmal I7 of 114 patients where emboli had occur- dysrhythmia, though this diagnosis could red (i5%), and in 75 of 44o patients with not be excluded. It was not possible to no history of embolism (i7%). determine the rhythm at the time of em- It has been thought that the size of the bolization in I8 (II'5%), and I07 (68 i%) atrial appendage has a direct influence on were in atrial fibrillation when examined. the clot formation therein, and hence the Nine (5 8%) had the atrial fibrillation for risk of embolus formation, both before and less than one month, and 6o (38 I%) for during operation (Somerville and Cham- more than one month when embolization bers, I964). If this could be proved true, occurred. In 38 (24I%) it was not possible then it would be of considerable value both to determine the duration of the atrial fibril- prognostically and in the planning of opera- lation. tion. We have tried to elucidate this problem In all, 28 patients with known rheumatic by an attempted radiological assessment of Br Heart J: first published as 10.1136/hrt.32.1.26 on 1 January 1970. Downloaded from 28 Coulshed, Epstein, McKendrick, Galloway, and Walker the left atrial appendage size in two different TABLE 3 Incidence ofpre-operative groups of patients. embolism in all cases operated upon, cor- The radiological assessment of the left related with valve calcification and cardiac atrial appendage from a standardized 6-foot rhythm postero-anterior x-ray was accomplished with reference to an imaginary line drawn from Rhythm I Pre-operative embolism No pre-operative embolism the left border of the aortic knuckle to the cardiac apex. Thus, grade o is where no Calcification Calcification Calcification Calcification present absent present absent atrial appendage shadow can be seen, grade I is where the appendage is visible on the Sinus 10 II 8i I83 left cardiac border but does not extend Atrial closer than 2 mm. to this line, grade 2 is fibrillation 37 56 78 98 where the left border ofthe appendage shadow lies from 2 mm. medial to 7 mm. lateral to the line, while grade 3 is where the appen- dage shadow extends beyond the lateral mitral stenosis and those cases in which was limits of grade 2, and often has a separate exploratory cardiotomy performed. was out on outline of its own. Operation carried 206 patients Pre-operative x-rays were assessed in 104 with valve calcification, 47 having had pre- patients known to have had systemic emboli, operative emboli (23%); 348 patients with- out calcification included who had and 53 were found to have an atrial appendage valve 67 suffered pre-operative emboli (:i%).
Load more

Recommended publications
  • Best Threshold for Diagnosis of Stenosis Or Thrombosis Within Six Months of Access Flow Measurement in Arteriovenous Fistulae
    J Am Soc Nephrol 14: 3264–3269, 2003 Best Threshold for Diagnosis of Stenosis or Thrombosis within Six Months of Access Flow Measurement in Arteriovenous Fistulae MARCELLO TONELLI,*†‡ GIAN S. JHANGRI,§ DAVID J. HIRSCH,ʈ¶ JOANNE MARRYATT,¶ PAULA MOSSOP,¶ COLLEEN WILE,¶ and KAILASH K. JINDAL* *Department of Medicine, University of Alberta, Edmonton, Canada; †Department of Critical Care, University of Alberta, Edmonton, Canada; ‡Institute of Health Economics, Edmonton, Canada; §Department of Public Health Sciences, University of Alberta, Edmonton, Canada; ʈDepartment of Medicine, Dalhousie University, Halifax, Canada; and ¶Queen Elizabeth II Health Sciences Centre, Halifax, Canada Abstract. Canadian clinical practice guidelines recommend within 6 mo, and both seemed superior to Ͻ400 ml/min. performing angiography when access blood flow (Qa) is Ͻ500 However, the frequency of the composite definition of stenosis ml/min in native vessel arteriovenous fistulae (AVF), but data among AVF with Qa between 500 and 600 ml/min was only 6 on the value of Qa that best predicts stenosis are sparse. (25%) of 24, as compared with 58 (76%) of 76 when Qa was Because correction of stenosis in AVF improves patency rates, Ͻ500 ml/min. This suggests that most lesions that would be this issue seems worthy of investigation. Receiver-operating found using a threshold of Ͻ600 ml/min occurred in AVF with characteristic curves were constructed to examine the relation- Qa Ͻ500 ml/min and that the small gain in sensitivity associ- ship between different threshold values of Qa and stenosis in ated with the Ͻ600-ml/min threshold would be outweighed by 340 patients with AVF.
    [Show full text]
  • Everything I Need to Know About Renal Artery Stenosis
    Patient Information Renal Services Everything I need to know about renal artery stenosis What is renal artery stenosis? Renal artery stenosis is the narrowing of the main blood vessel running to one or both of your kidneys. Why does renal artery stenosis occur? It is part of the process of arteriosclerosis (hardening of the arteries), that develops in very many of us as we get older. As well as becoming thicker and harder, the arteries develop fatty deposits in their walls which can cause narrowing. If the kidneys are affected there is generally also arterial disease (narrowing of the arteries) in other parts of the body, and often a family history of heart attack or stroke, or poor blood supply to the lower legs. Arteriosclerosis is a consequence of fat in our diet, combined with other factors such as smoking, high blood pressure and genetic factors inherited, it may develop faster if you have diabetes. What are the symptoms? You may have fluid retention, where the body holds too much water and this can cause breathlessness, however often there are no symptoms. The arterial narrowing does not cause pain, and urine is passed normally. As a result this is usually a problem we detect when other tests are done, for example, routine blood test to measure how well your kidneys are working. What are the complications of renal artery stenosis? Kidney failure, if the kidneys have a poor blood supply, they may stop working. This can occur if the artery blocks off suddenly or more gradually if there is serious narrowing.
    [Show full text]
  • Pacemaker Syndrome Pacemaker Therapy Has Become an Important Therapeutic Option for Patients with Heart Rhythm Conditions Worldwide
    360 Cardiology Pacemaker syndrome Pacemaker therapy has become an important therapeutic option for patients with heart rhythm conditions worldwide. Te number of elderly patients needing pacemakers is on the increase due to an ageing population worldwide. Pacemaker syndrome consists of the cardiovascular signs and symptoms of heart failure and hypotension induced by right ventricular (RV) pacing. Dr Satnam Singh Research Registrar, University of Aberdeen, Level 3, Polwarth building, Aberdeen email [email protected] Pacemaker syndrome is a term syndrome occurring in dual trial was a single blinded study proposed in 1979 by Erbel and chamber modes.5,6 It can even enrolling around 2000 patients refers to symptoms and signs in occur with AAI pacing with long with sick sinus syndrome. the pacemaker patient caused by PR intervals. All patients were implanted inadequate timing of atrial and dual chamber pacemakers ventricular contractions.1 It was first programmed to VVIR or DDDR described in 1969 by Mitsui et al2 as Incidence before implantation. Pacemaker an iatrogenic disease characterised syndrome was a secondary by the disappearance of symptoms Te overall incidence of pacemaker endpoint studied. Severe with restoration of atrioventricular syndrome is very difficult to pacemaker syndrome developed synchrony (AV synchrony). estimate but is about 20% in a in nearly 20% of VVIR-paced It means if atria and ventricles landmark trial called the Mode patients and improved with contract at appropriate timings (as Selection Trial (MOST).7 It occurs reprogramming to the dual- close to physiological), pacemaker with equal frequency in both sexes chamber pacing mode. syndrome can be prevented.
    [Show full text]
  • Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management From
    REVIEW ARTICLE Hereditary hemorrhagic telangiectasia: Ferrata Storti diagnosis and management from Foundation the hematologist’s perspective Athena Kritharis,1 Hanny Al-Samkari2 and David J Kuter2 1Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ and 2Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ABSTRACT Haematologica 2018 Volume 103(9):1433-1443 ereditary hemorrhagic telangiectasia (HHT), also known as Osler- Weber-Rendu syndrome, is an autosomal dominant disorder that Hcauses abnormal blood vessel formation. The diagnosis of hered- itary hemorrhagic telangiectasia is clinical, based on the Curaçao criteria. Genetic mutations that have been identified include ENG, ACVRL1/ALK1, and MADH4/SMAD4, among others. Patients with HHT may have telangiectasias and arteriovenous malformations in various organs and suffer from many complications including bleeding, anemia, iron deficiency, and high-output heart failure. Families with the same mutation exhibit considerable phenotypic variation. Optimal treatment is best delivered via a multidisciplinary approach with appropriate diag- nosis, screening and local and/or systemic management of lesions. Antiangiogenic agents such as bevacizumab have emerged as a promis- ing systemic therapy in reducing bleeding complications but are not cur- ative. Other pharmacological agents include iron supplementation, antifibrinolytics and hormonal treatment. This review discusses the biol- ogy of HHT, management issues that face
    [Show full text]
  • How to Define Valvular Atrial Fibrillation?
    Archives of Cardiovascular Disease (2015) 108, 530—539 Available online at ScienceDirect www.sciencedirect.com REVIEW How to define valvular atrial fibrillation? Comment définir la fibrillation atriale valvulaire ? ∗ Laurent Fauchier , Raphael Philippart, Nicolas Clementy, Thierry Bourguignon, Denis Angoulvant, Fabrice Ivanes, Dominique Babuty, Anne Bernard Service de cardiologie, faculté de médecine, université Franc¸ois-Rabelais, CHU Trousseau, Tours, France Received 3 June 2015; accepted 8 June 2015 Available online 14 July 2015 KEYWORDS Summary Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials compar- Atrial fibrillation; ing vitamin K antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in Valve disease; AF were performed among patients with so-called ‘‘non-valvular’’ AF. The distinction between Stroke ‘‘valvular’’ and ‘‘non-valvular’’ AF remains a matter of debate. Currently, ‘‘valvular AF’’ refers to patients with mitral stenosis or artificial heart valves (and valve repair in North American guidelines only), and should be treated with VKAs. Valvular heart diseases, such as mitral regur- gitation, aortic stenosis (AS) and aortic insufficiency, do not result in conditions of low flow in the left atrium, and do not apparently increase the risk of thromboembolism brought by AF. Post-hoc analyses suggest that these conditions probably do not make the thromboembolic risk less responsive to NOACs compared with most forms of ‘‘non-valvular’’ AF. The pathogenesis of thrombosis is probably different for blood coming into contact with a mechanical prosthetic valve compared with what occurs in most other forms of AF. This may explain the results of the only trial performed with a NOAC in patients with a mechanical prosthetic valve (only a few of whom had AF), where warfarin was more effective and safer than dabigatran.
    [Show full text]
  • Mitral Stenosis and Atrial Fibrillation Funding the Authors Have Not Declared a Specific Heart: First Published As 10.1136/Heartjnl-2019-316282 on 6 February 2020
    Editorial Contributors DW and BS wrote the editorial together. Mitral stenosis and atrial fibrillation Funding The authors have not declared a specific Heart: first published as 10.1136/heartjnl-2019-316282 on 6 February 2020. Downloaded from grant for this research from any funding agency in the Dirk Westermann , Benedikt Schrage public, commercial or not- for- profit sectors. Competing interests None declared. Patient consent for publication Not required. Over the past decades, the incidence of Health Insurance Review and Assessment mitral stenosis (MS) due to rheumatic Service database, which covers 98% of the Provenance and peer review Commissioned; internally peer reviewed. fever has markedly decreased. Regardless, overall South Korean population, Kim et rheumatic fever remains associated with al4 describe a cohort of 42 075 patients about 80% of all cases of MS, and so rela- diagnosed with MS between 2007 and tively the most relevant contributor to 2016. In their study, the authors observed MS.1 Aside from rare causes such as a decreasing incidence of MS during the congenital MS, MS due to myxoma or MS study period, from 10.3 to 3.6 cases per following infiltrating diseases, another 100 000 inhabitants. While this data source Open access This is an open access article distributed in accordance with the Creative Commons Attribution important cause of MS is indeed severe does not allow indepth analysis of patient Non Commercial (CC BY- NC 4.0) license, which permits calcification of the mitral annulus and its data, it is important due to the large popu- others to distribute, remix, adapt, build upon this work leaflets.
    [Show full text]
  • Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Impact, and Management
    Heart Failure Reviews (2019) 24:189–197 https://doi.org/10.1007/s10741-018-9752-6 Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management Lohit Garg 1 & Manasvi Gupta2 & Syed Rafay Ali Sabzwari1 & Sahil Agrawal3 & Manyoo Agarwal4 & Talha Nazir1 & Jeffrey Gordon1 & Babak Bozorgnia1 & Matthew W. Martinez1 Published online: 19 November 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hyper- trophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardio- graphic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes. Keywords Atrial fibrillation . Hypertrophic cardiomyopathy . Treatment . Antiarrhythmic agents Introduction amyloidosis) [3–5]. The clinical presentation of HCM is het- erogeneous and includes an asymptomatic state, heart failure Hypertrophic cardiomyopathy (HCM) is the most common syndrome due to diastolic dysfunction or left ventricular out- inherited cardiomyopathy due to mutation in one of the sev- flow (LVOT) obstruction, arrhythmias (atrial fibrillation and eral sarcomere genes and transmitted in autosomal dominant embolism), and sudden cardiac death [1, 6].
    [Show full text]
  • A Successful Intra-Pleural Fibrinolytic Therapy with Alteplase in a Patient with Empyematous Multiloculated Chylothorax
    CASE REPORT East J Med 24(3): 379-382, 2019 DOI: 10.5505/ejm.2019.72621 A Successful Intra-Pleural Fibrinolytic Therapy With Alteplase in A Patient with Empyematous Multiloculated Chylothorax Mohamed Faisal1*, Rayhan Amiseno1, Nurashikin Mohammad2 1Respiratory Unit, Universiti Kebangsaan Malaysia Medical Centre, Malaysia 2Medical Department, Universiti Sains Malaysia ABSTRACT Chylothorax is a collection of chyle in the pleural cavity resulting from leakage of lymphatic vessels, usually from the thoracic duct. In majority of cases, chylothorax is a bacteriostatic pleural effusion. Incidence of infected or even empyematous chylothorax are not common. Here, we report a case of a 57-year-old man with end stage renal disease and complete central venous stenosis who presented with recurrent right-sided chylothorax. It was complicated with sepsis and multilocated empyema and treated successfully with intra-pleural fibrinolytic therapy using alteplase. Key Words: Chylothorax, empyema, intrapleural fibrinolysis Introduction effusions and empyema in the adult population for the outcomes of treatment failure (surgical Chyle is a non-inflammatory, bacteriostatic fluid intervention or death) and surgical intervention with a variable protein, fat and a lymphocyte alone (4). Our patient had chylothorax which was predominance of the total nucleated cells. (1,2) complicated with empyema and treated with Incidence data are available for only post- combination of intravenous antibiotic and operative chylothorax, which can occur after sequential intra-pleural alteplase (without almost any surgical operation in the chest. It is deoxyribonuclease) administered to different most often observed after esophagectomy (about pleural locules. 3% of cases), or after heart surgery in children (up to about 6% of cases) (1).
    [Show full text]
  • Large Coronary Artery Aneurysm with Thrombotic Coronary Occlusion Resulting in ST-Elevation Myocardial Infarction After Warfarin Interruption
    Case Report http://dx.doi.org/10.12997/jla.2014.3.2.105 pISSN 2287-2892 • eISSN 2288-2561 JLA Large Coronary Artery Aneurysm with Thrombotic Coronary Occlusion Resulting in ST-Elevation Myocardial Infarction after Warfarin Interruption Jun-Hyoung Kim1, Hyung-Bok Park2, Young-Bae Lee1, Jae-Hyuk Lee1, Myung-Sung Kim1, Che-Wan Lim1, Deok-Kyu Cho2 1Department of Internal Medicine, Myongji Hospital, Goyang, 2Division of Cardiology, Cardiovascular Center, Myongji Hospital, Goyang, Korea A 44-year-old man, who had a history of myocardial infarction (MI) due to thrombotic occlusion of right coronary artery (RCA) aneurysm, visited emergency department presenting with ST-segment elevation myocardial infarction (STEMI). The patient had been on oral anticoagulant therapy (warfarin) from the first thrombotic event, but the medication had been recently changed to aspirin 4 months before the second event. Emergent coronary angiography revealed thrombotic total occlusion of RCA with heavy thrombotic burden from middle RCA to the ostium of the posterior descending branch. Combination pharmacotherapy was performed with anticoagulants (heparin), fibrinolytics (urokinase), and Glycoprotein IIb/IIIa antagonists (abciximab), in addition to mechanical thrombosuction. However, on hospital day 2, the patient complained recurrent chest pain and again underwent coronary angiography, which revealed distal embolization of large thrombus to the posterior lateral branch. Coronary flow was recovered after repeated mechanical thrombosuction was performed. This case has shown the importance of aggressive combination drug therapy, accompanied by mechanical thrombosuction in patient with myocardial infarction due to thrombotic occlusion of coronary artery aneurysm and the importance of unceasing life-long anticoagulant therapy in those particular patients.
    [Show full text]
  • Vascular Disease in the Elderly
    Chapter 13: Vascular Disease in the Elderly Nobuyuki Bill Miyawaki* and Paula E. Lester† *Division of Nephrology and †Division of Geriatrics, Winthrop University Hospital, Mineola, New York PHYSIOLOGIC EFFECTS OF AGING ON stiffening of medium and large arteries lined with BLOOD VESSEL ELASTICITY AND atheromatous plaques. The progressive accumula- COMPLIANCE tion of atherosclerotic plaque continues with aging and often remains silent until lesions reach a critical The aging process is commonly associated with in- stenotic threshold or rupture, leading to dimin- creased vascular rigidity and decreased vascular ished organ perfusion. Arterial stiffening also leads compliance. This process reflects the accumulation to an increase in pulse wave velocity and an en- of smooth muscle cells and connective tissue in the hancement in central aortic systolic pressure.3 The walls of major blood vessels. Endothelial cells and increased waveform velocity allows the backward smooth muscle cells constitute most of vessel wall reflective wave to return earlier back to the heart. cellularity and the remainder of the wall is com- The resulting increases of the left ventricular myo- posed of extracellular matrix including collagen cardial load and the loss of coronary perfusion at and elastin. Although aging has minimal effect on the onset of diastole may potentiate myocardial the muscular tunica media layer thickness, aging ischemia.3 leads to profound progressive thickening of the tu- Common ailments in the elderly including dia- nica intima layer comprised
    [Show full text]
  • Treatment of Atrial Fibrillation in Hypertrophic Cardiomyopathy Hipertrofik Kardiyomiyopatide Atriyal Fibrilasyonun Tedavisi
    44 Treatment of atrial fibrillation in hypertrophic cardiomyopathy Hipertrofik kardiyomiyopatide atriyal fibrilasyonun tedavisi Khashayar Hematpour, Jonathan S. Steinberg Division of Cardiology, St. Luke's-Roosevelt Hospital Center, New York, NY, USA ABSTRACT Atrial fibrillation (AF) is present in 5 percent of hypertrophic cardiomyopathy (HCM) patients at the time of diagnosis. Ostial pulmonary vein (PV) diameter is increased in patients with AF as well as hypertensive patients. These findings support the theory that the cascade of events leading to diastolic dysfunction might predispose a person to AF by stretching the PVs. This mechanism is likely relevant to AF in HCM as well. The recognition that AF often times arises from the PVs has led to innovation of ablation techniques that target this zone to electrically isolate the PVs from the left atrium (LA). Anticoagulation is the cornerstone of AF treatment. Additional AF treatment in HCM patients de- pends on the initial decision regarding need for surgical intervention, whether or not AF is permanent, and the severity of symptoms in pati- ents with non-permanent AF. If surgery is planned, correction of the arrhythmia with MAZE procedure, which isolates the arrhythmogenic foci, at the time of myectomy is an option to consider. The goal in HCM patients with permanent AF is to control the heart rate whether by chronic medications or through ablate + pace procedure. Based on the severity of symptoms, HCM patients with non-permanent AF will be treated with either the rate control strategy (β-blockers/calcium channel blocker) or the rhythm control strategy (PV ablation, antiarrhyth- mic drugs, or radiofrequency ablation of the LA).
    [Show full text]
  • Pacemaker Syndrome: an Iatrogenic Condition
    Br Heart J 1992;68:163-6 163 VIEWPOINT Pacemaker syndrome: an iatrogenic condition Christopher M Travill, Richard Sutton Pacemaker syndrome was first described in inhibited (VVI) pacing was used. In the re- 1969 by Mitsui when it was referred to as the maining 20 patients with no history of pacemaking syndrome.' The name pacemaker pacemaker syndrome or ventriculoatrial con- syndrome was first coined by Erbel (using the duction Doppler derived cardiac output German Schrittmacher syndrom) in 1979.2 It improved by 14% when pacing was changed can present with symptoms as severe as to DDD from VVI.8 syncope, presyncope, oedema, dyspnoea, and chest pain, or more moderately and subtly as lethargy, palpitation, or an awareness of Haemodynamics of pacemaker venous pulsation all of which may occur when syndrome there is atrial systole during ventricular sys- Contraction of the atria against closed atrio- tole. This is most frequent when there is ventricular valves during ventricular systole ventriculoatrial conduction from the paced leads to raised atrial pressures, loss of atrial ventricle to the atrium usually via the contribution to ventricular filling, and a con- atrioventricular node.34 The symptoms can be sequent fall in cardiac output which causes a identical to those prompting implant.5 fall in arterial pressure if the baroreceptor Occasionally pacemaker syndrome can occur mediated rise in systemic vascular resistance is in the absence of ventriculoatrial conduction insufficient.9 In a study on 20 open-chest dogs when ventricular pacing is in competition with experimental complete heart block left with sinus rhythm.6 atrial angiography showed retrograde blood flow into the pulmonary venous system at Incidence of pacemaker syndrome atrioventricular intervals of -50 and The incidence of pacemaker syndrome varies - 100 ms.
    [Show full text]